DexCom, Inc. vs Lamb Weston Holdings Inc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Lamb Weston Holdings Inc trades at $48.22 (market cap $6.81B). The key difference: DexCom, Inc. is far larger — about 4.7× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lamb Weston Holdings Inc for 66 Days on average.
| DXCM | LW | |
|---|---|---|
Market Cap | $31.86B | $6.81B |
Volume | 3,607,070 | 4,638,686 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $66.57 |
52-Week Low | $54.84 | $38.48 |
Typical Hold Time | 62 Days | 66 Days |
Enterprise Value | $31.32B | $10.61B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Lamb Weston (LW) trades at $48.09, up 0.38% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost savings exceeding $100 million and analyst anticipation for upcoming Q1 earnings. The consensus price target is $53.71, suggesting potential upside from current levels.
The outlook is cautiously optimistic, supported by earnings momentum and operational improvements, but risks include margin pressure from rising costs and a high debt load. Investor sentiment is mixed amid legal scrutiny and institutional selling, requiring careful monitoring of execution against guidance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →